AIGH资本公司在Tarsus制药公司(一家生物制药公司)的股份增加了近10%。 AIGH Capital boosted its stake in Tarsus Pharmaceuticals, a biopharmaceutical firm, by nearly 10%.

AIGH资本管理有限公司将塔索斯制药公司的投资增加了9.9%,现在拥有224 713股股份,成为该公司第10大股。 AIGH Capital Management LLC increased its investment in Tarsus Pharmaceuticals by 9.9%, now owning 224,713 shares, making it the firm's 10th largest holding. Tarsus制药公司是一家以眼科护理为重点的生物制药公司,其主要产品候选者XDEMVY是治疗脑膜炎和脑膜腺病。 Tarsus Pharmaceuticals, a biopharmaceutical company focusing on eye care, has a lead product candidate, XDEMVY, for treating blepharitis and meibomian gland disease. 股票有一个一致的“Buy”评级,平均目标价格为63.67美元。 The stock has a consensus "Buy" rating and an average target price of $63.67. 机构投资者持有Tarsus制药公司的股票的90.01%,最近从AIGH和谨慎金融公司购买了股票。 Institutional investors hold 90.01% of Tarsus Pharmaceuticals' stock, with recent buys from AIGH and Prudential Financial Inc.